A Phase II Study of Poziotinib and Ramucirumab in EGFR Exon 20 Mutant Advanced Non-small Cell Lung Cancer (NSCLC)
Latest Information Update: 18 Feb 2023
Price :
$35 *
At a glance
- Drugs Poziotinib (Primary) ; Ramucirumab (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Feb 2023 Status changed from not yet recruiting to withdrawn prior to enrolment due to funding (0 patient accrual).
- 18 Jul 2022 Planned initiation date changed from 28 Feb 2022 to 28 Feb 2023.
- 28 Jan 2022 Planned initiation date changed from 30 Dec 2021 to 28 Feb 2022.